Assessing The Future Of Coronary Stenting: An Interview With Dean J. Kereiakes, MD
Dean Kereiakes, MD, a PI for Abbott Vascular’s ABSORB III US pivotal trial, discusses the future of coronary stenting and provides his unique perspective on the potential role of bioresorbable vascular scaffolds for the treatment of coronary artery disease.
You may also be interested in...
Bioresorbable coronary scaffolds could transform the coronary stenting market once they become widely available. But although there are more than a dozen companies developing these promising devices, there are still a number of unanswered questions – chief among them, how effectively they will compete against existing and upcoming next-generation durable stents, and how much of a price premium bioresorbable devices will be able to command.
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.